Humphries Holly E, Brookes Charlotte, Allen Lauren, Kuisma Eeva, Gorringe Andrew, Taylor Stephen
Public Health England, Porton Down, Salisbury, United Kingdom
Public Health England, Porton Down, Salisbury, United Kingdom.
Clin Vaccine Immunol. 2015 May;22(5):503-9. doi: 10.1128/CVI.00100-15. Epub 2015 Mar 4.
The correlate of protection for the licensure of meningococcal vaccines is serum bactericidal activity. However, evidence indicates that a complex situation and other mechanisms, such as antibody-mediated, complement-dependent opsonophagocytosis (OP), may play a role in protection and should be investigated in order to understand immunity to this disease. In this study, a high-throughput flow cytometric opsonophagocytic assay (OPA) was optimized. The assay measures the presence of killed fluorescently labeled Neisseria meningitidis within human granulocytes (differentiated HL60 cells) by flow cytometry, using IgG-depleted pooled human plasma as an exogenous source of complement. This method was found to be reliable and correlated with the results of an opsonophagocytic killing assay. The OPA was used to measure OP activity in 1,878 serum samples from individuals ranging from 0 to 99 years of age against N. meningitidis strain NZ98/254 (B:4:P1.7-2,4). The levels of OP activity in individual serum samples varied greatly. OP activity showed an initial peak in the 6- to 12-month age group corresponding to a peak in disease incidence. The OP activity dropped in childhood until the late teenage years, although there was still a higher percentage of individuals with OP activity than with protective bactericidal antibody titers. OP activity reached a peak in the 30- to 39-year age group and then declined. This later peak in OP activity did not coincide with the young adults in whom peak serum bactericidal activity and disease incidence occurred. The demonstration of OP activity when disease incidence is low and when protective bactericidal antibody titers are not detected may indicate a role for OP in protection from meningococcal disease in these age groups.
脑膜炎球菌疫苗获得许可的保护相关指标是血清杀菌活性。然而,有证据表明,情况较为复杂,其他机制,如抗体介导的补体依赖调理吞噬作用(OP),可能在保护中发挥作用,为了解对该疾病的免疫情况,应对其进行研究。在本研究中,对一种高通量流式细胞术调理吞噬测定法(OPA)进行了优化。该测定法通过流式细胞术,以去除IgG的混合人血浆作为外源性补体来源,测量人粒细胞(分化的HL60细胞)内被杀死的荧光标记脑膜炎奈瑟菌的存在情况。发现该方法可靠,且与调理吞噬杀伤测定结果相关。OPA用于测量1878份年龄从0到99岁个体的血清样本针对脑膜炎奈瑟菌菌株NZ98/254(B:4:P1.7 - 2,4)的OP活性。个体血清样本中的OP活性水平差异很大。OP活性在6至12月龄年龄组出现首个峰值,这与疾病发病率的峰值相对应。OP活性在儿童期下降,直至青少年晚期,尽管具有OP活性的个体百分比仍高于具有保护性杀菌抗体滴度的个体百分比。OP活性在30至39岁年龄组达到峰值,然后下降。OP活性的这一后期峰值与血清杀菌活性峰值和疾病发病率出现峰值的年轻成年人并不一致。在疾病发病率较低且未检测到保护性杀菌抗体滴度时OP活性的表现,可能表明OP在这些年龄组预防脑膜炎球菌疾病中发挥作用。